SBIR/STTR Research Award
PRO 542 Immunotherapy of Advanced HIV 1 Disease
Award amount
$591,376Program and phase
SBIR · Phase IAward year
2004Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PROGENICS PHARMACEUTICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- YLYKVRPCTCR3
- Solicitation number
- PHS2004-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Despite important advances in HIV-1 therapy over the past decade, most patients eventually exhaust their therapeutic options due to the emergence of multidrug-resistant virus and to the development of intolerable trea
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- PSMA Antibody-Drug Conjugate for Prostate Cancer Therapy
- PSMA-VRP vaccine for prostate cancer
- Broadly Neutralizing MAbs against Hepatitis C Virus
- Novel small-molecule inhibitors of HIV-1 Vif
- Broadly Inhibitory MAbs Targeting Hepatitis C Virus Receptors
Research funding history
39 SBIR/STTR records share this UEI (1990–2007). Reported award amounts total $29,853,777. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services